

Table 3. Results from KEYNOTE-059²⁶

Study & patient arm	Median overall survival (months)	Progression free survival (months)	Objective response rate (ITT)
KEYNOTE-059 cohort 2* Pembrolizumab plus chemotherapy	13.8 (95% CI 8.6-not estimable)	6.6 (95% CI 5.9-10.6)	60.0% (95% CI 39.0-79.0)
KEYNOTE-059 cohort 3** Pembrolizumab monotherapy	20.7 (95% CI 9.2-20.7)	3.3 (95% CI 2.0-6.0)	25.8% (95% CI 11.9-44.6%),

CI: confidence interval; CPS: combined positive score; HR: hazard ratio; ITT: intention-to-treat population; NR: not recorded

*CPS \geq 1 (n = 16 [64%]), CPS < 1 (n = 8 [32%]), CPS unknown (n = 1 [4%])

**CPS \geq 1 (n = 31 [100%])